Jim Cramer - Mad Money ARS Pharmaceuticals SPRY-Q RISKY Apr 22, 2024

Speculative, but we need more pharma companies to make immunotherapy drugs.

Jim Cramer - Mad Money

Unknown

Unlock Rating

N/A

Stock price when the opinion was issued

Pharma & Healthcare

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

BUY

He likes their model, and there is no demand for their products.

Most Recent Experts

John Hood

Croft Financial Group

Stockchase Insights

5i Research

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Sarat Sethi, Managing Partner, Douglas C. Lane & Assoc.

Douglas C. Lane & Assoc.

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

Jim Cramer - Mad Money ARS Pharmaceuticals SPRY-Q RISKY Apr 22, 2024

You might be interested:

ARS Pharmaceuticals(SPRY-Q)

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals